Patents by Inventor H. Kim Bottomly
H. Kim Bottomly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8815251Abstract: The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.Type: GrantFiled: January 16, 2013Date of Patent: August 26, 2014Assignee: Allertein Therapeutics, LLCInventors: Michael J. Caplan, Howard B. Sosin, H. Kim Bottomly, A. Wesley Burks, Jr., Hugh A. Sampson
-
Publication number: 20130243814Abstract: The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.Type: ApplicationFiled: January 16, 2013Publication date: September 19, 2013Applicant: ALLERTEIN THERAPEUTICS, LLCInventors: Michael J. Caplan, Howard B. Sosin, H. Kim Bottomly, A. Wesley Burks, JR., Hugh A. Sampson
-
Publication number: 20130142817Abstract: The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.Type: ApplicationFiled: July 19, 2012Publication date: June 6, 2013Applicant: ALLERTEIN THERAPEUTICS, LLCInventors: Michael J. Caplan, Hugh A. Sampson, A. Wesley Burks, H. Kim Bottomly, Howard B. Sosin
-
Patent number: 8246945Abstract: The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as E. coli. Any allergen may be used in the inventive methods. Particularly preferred allergens are anaphylactic allergens including protein allergens found in foods, venoms, drugs and latex. The inventive compositions and methods are demonstrated in the treatment of peanut-induced anaphylaxis.Type: GrantFiled: October 2, 2009Date of Patent: August 21, 2012Assignees: University of Arkansas, Mount Sinai School of Medicine of New York University, Allertein Therapeutics, LLCInventors: Michael J. Caplan, H. Kim Bottomly, Howard B. Sosin, A. Wesley Burks, Hugh A. Sampson
-
Patent number: 8153414Abstract: The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.Type: GrantFiled: December 6, 2000Date of Patent: April 10, 2012Assignee: Allertein Therapeutics, LLCInventors: Michael J. Caplan, Hugh A. Sampson, A. Wesley Burks, H. Kim Bottomly, Howard B. Sosin
-
Publication number: 20110027298Abstract: The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.Type: ApplicationFiled: July 26, 2010Publication date: February 3, 2011Applicant: ALLERTEIN THERAPEUTICS, LLCInventors: Michael J. Caplan, Hugh A. Sampson, A. Wesley Burks, H. Kim Bottomly, Howard B. Sosin
-
Publication number: 20100166802Abstract: The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as E. coli. Any allergen may be used in the inventive methods. Particularly preferred allergens are anaphylactic allergens including protein allergens found in foods, venoms, drugs and latex. The inventive compositions and methods are demonstrated in the treatment of peanut-induced anaphylaxis.Type: ApplicationFiled: October 2, 2009Publication date: July 1, 2010Inventors: Michael J. Caplan, H. Kim Bottomly, Howard B. Sosin, A. Wesley Burks, Hugh A. Sampson
-
Publication number: 20040156821Abstract: The present invention provides compositions and methods for regulating immune system reactions by biasing T cell responses away from Th1 or Th2 responses in a pre-determined manner. Control is effected at the stage of antigen/APC encounter and/or at the stage of APC/T cell encounter. In preferred embodiments, a Th1 or Th2 response is inhibited through induction of the alternative response. The inventive methods and reagents are particularly useful for the management of autoimmune disorders, allergy, and asthma.Type: ApplicationFiled: February 10, 2004Publication date: August 12, 2004Inventors: H. Kim Bottomly, Michael J. Caplan, Howard B. Sosin
-
Publication number: 20040076646Abstract: The present invention provides techniques and reagents that induce an immune response against tumor cells. According to the invention, tumor cell components are contacted with a sensitizing agent, preferably so that one or more tumor cell components become haptenized with a sensitizing agent, and the resulting combination is administered to a patient suffering from a tumor, so that an anti-tumor immune response is mounted. In some embodiments of the invention, sensitizing agent/tumor cell component compositions are administered directly to a patient; in other embodiments they are administered by means of an antigen presenting cell such as a dendritic cell.Type: ApplicationFiled: July 17, 2002Publication date: April 22, 2004Inventors: Michael J. Caplan, H. Kim Bottomly
-
Publication number: 20020090381Abstract: The present invention provides compositions and methods for regulating immune system reactions by biasing T cell responses away from Th1 or Th2 responses in a pre-determined manner. Control is effected at the stage of antigen/APC encounter and/or at the stage of APC/T cell encounter. In preferred embodiments, a Th1 or Th2 response is inhibited through induction of the alternative response. The inventive methods and reagents are particularly useful for the management of autoimmune disorders, allergy, and asthma.Type: ApplicationFiled: April 9, 1999Publication date: July 11, 2002Inventors: H. KIM BOTTOMLY, MICHAEL J. CAPLAN, HOWARD B. SOSIN